- Conditions
- Pancreatic Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Endoscopic Ultrasound-Guided Fine-Needle Aspiration, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure
- Procedure · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 770 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2034
- U.S. locations
- 413
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 294 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 534
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Solid Tumors, Adult
- Interventions
- STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 28
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
- Conditions
- Acute Ischemic Stroke
- Interventions
- Argatroban, Eptifibatide, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Fullerton, California • La Jolla, California + 47 more
- Conditions
- Ventricular Tachycardia
- Interventions
- Intrinsic Antitachycardia Pacing (iATP) Therapy
- Device
- Lead sponsor
- Medtronic
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 51
- States / cities
- Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 44 more
- Conditions
- Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
- Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1021
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 643 more
- Conditions
- Alcohol Consumption, Tobacco Use
- Interventions
- Nicotine, Ethanol
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Multiple Chronic Conditions, Decision Making, Shared
- Interventions
- Patient Priorities Care, Usual Care
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 65 Years and older
- Enrollment
- 437 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- West Haven, Connecticut • Houston, Texas
- Conditions
- Metastatic Prostate Cancer
- Interventions
- High dose testosterone
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • West Haven, Connecticut • Gainesville, Florida + 14 more
- Conditions
- Hypertension
- Interventions
- ATHENA-CDS-HTN plus Guideline Link, Guideline Link Only
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Not listed
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Newington, Connecticut • West Haven, Connecticut + 4 more
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Hilar Cholangiocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Childhood Liver Cancer, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Stage II Gallbladder Cancer, Stage III Childhood Hepatocellular Carcinoma, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Childhood Hepatocellular Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma
- Interventions
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium, Trametinib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 295
- States / cities
- Anchorage, Alaska • Anaheim, California • Auburn, California + 189 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Pembrolizumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 533
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 340 more
- Conditions
- B Acute Lymphoblastic Leukemia
- Interventions
- Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 455
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 279 more
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 136
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b2, Placebo, BNT162b2 OMI, Combination BNT162b2 and BNT162b2 OMI, Combination (Bivalent) BNT162b2 and BNT162b2 OMI
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 16,372 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 139
- States / cities
- Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 99 more
- Conditions
- Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Not listed
- Enrollment
- 150,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2030
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 50 more
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Selpercatinib
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 306
- States / cities
- Fairbanks, Alaska • Little Rock, Arkansas • Anaheim, California + 251 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
- Interventions
- Biospecimen Collection, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 2,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 955
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 654 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Questionnaire Administration, Temozolomide
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 418
- States / cities
- Fairbanks, Alaska • Fayetteville, Arkansas • Little Rock, Arkansas + 304 more
- Conditions
- Opioid Use Disorder
- Interventions
- CBOC offering Tele-MOUD to Veterans, CBOC not offering Tele-MOUD to Veterans
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- West Haven, Connecticut • Augusta, Maine
- Conditions
- Heart Failure
- Interventions
- Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,587 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
- Conditions
- Cognitive Impairment, Schizophrenia
- Interventions
- Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG), Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG), Skills Group (SDG)
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Doxorubicin Hydrochloride, Filgrastim, Magnetic Resonance Imaging, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Vinblastine Sulfate
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 711
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 472 more
- Conditions
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Interventions
- Cobomarsen, Vorinostat
- Drug
- Lead sponsor
- miRagen Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more
- Conditions
- Stage I Breast Cancer
- Interventions
- Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
- Other · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 1,670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2041
- U.S. locations
- 812
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more